Literature DB >> 34353991

Partial Versus Total Thyroidectomy: What Influences Most Surgeons' Decision? Analysis of a Nationwide Cohort of 375,810 Patients Over 10 Years.

Camille Marciniak1, Xavier Lenne, Guillaume Clément, Amélie Bruandet, Jean-Christophe Lifante, Frédéric Sebag, Eric Mirallié, Muriel Mathonnet, Laurent Brunaud, Gianluca Donatini, Christophe Tresallet, Fabrice Ménégaux, Didier Theis, François Pattou, Robert Caiazzo.   

Abstract

National and international guidelines about thyroid surgery seem to be moving more and more towards less radical surgical procedures but everyday practice does not seem to always align with them. We describe for the first time the role of non-surgical parameters in the surgeon's choice for thyroid surgery.
OBJECTIVE: To describe thyroid surgery and to identify the factors leading to either a total or a partial thyroidectomy regardless of the severity of the thyroid disease. SUMMARY BACKGROUND DATA: National and international guidelines about thyroid surgery seem to be moving more and more towards less radical surgical procedures but everyday practice does not seem to always align with them.
METHODS: We based this nationwide retrospective cohort study on a national database that compiles discharge abstracts for every admission for thyroidectomy to French acute healthcare facilities (PMSI database 2010 to 2019).
RESULTS: In this study, 375,810 patients (male: 23%; age = 53 ± 15 y) had a thyroidectomy (partial: 28%) for cancer (17%), hyperthyroidism (16%), non-functioning goiter (64%) or other (3%). We noticed a global trend toward more partial thyroidectomy (p < 0.001) with a significant increase in the proportion of lobectomy in the post-ATA recommendations' period (p < 0.001) as well as in the "French Levothyrox crisis" period, in which we saw an unexpected rise of adverse events notifications associated with the marketing of a new formula of Levothyrox (p < 0.001) amid widespread media coverage. In a multivariate analysis, we also identified that complete resection was more frequently performed in centers with a caseload > 40/y (p < 0.001, OR = 1.48), for obese patients (BMI> 30 kg/m2; p < 0.001, OR = 1.42), and according to the indication of surgery (OR benign = 1, OR cancer = 2.25, OR hyperthyroidism = 4.13).
CONCLUSION: We describe for the first time the role of non-surgical parameters in the surgeon's choice for thyroid surgery.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 34353991     DOI: 10.1097/SLA.0000000000005134

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  4 in total

1.  Impact of the 2015 American thyroid association guidelines on treatment in older adults with low-risk, differentiated thyroid cancer.

Authors:  Whitney Sutton; Philip K Crepeau; Joseph K Canner; Shkala Karzai; Dorry L Segev; Aarti Mathur
Journal:  Am J Surg       Date:  2022-02-01       Impact factor: 3.125

2.  Trends in the Management of Localized Papillary Thyroid Carcinoma in the United States (2000-2018).

Authors:  Elisa Pasqual; Julie Ann Sosa; Yingxi Chen; Sara J Schonfeld; Amy Berrington de González; Cari M Kitahara
Journal:  Thyroid       Date:  2022-03-15       Impact factor: 6.506

3.  Clinicopathological and surgical comparisons of differentiated thyroid cancer between China and the USA: A multicentered hospital-based study.

Authors:  Juan Zhu; Kexin Sun; Jian Wang; Yutong He; Daojuan Li; Shuzheng Liu; Yunchao Huang; Min Zhang; Bingbing Song; Xianzhen Liao; He Liang; Qian Zhang; Mumu Shi; Lanwei Guo; Yongchun Zhou; Yanping Lin; Yanni Lu; Jiyu Tuo; Yafen Xia; Huixin Sun; Haifan Xiao; Yong Ji; Ci Yan; Jinwan Qiao; Hongmei Zeng; Rongshou Zheng; Siwei Zhang; Shaoyan Liu; Sheng Chang; Wenqiang Wei
Journal:  Front Public Health       Date:  2022-09-28

4.  Optimal Surgical Extent in Patients with Unilateral Multifocal Papillary Thyroid Carcinoma.

Authors:  Joohyun Woo; Hyungju Kwon
Journal:  Cancers (Basel)       Date:  2022-01-15       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.